Skip to NavigationSkip to content

Remdesivir cuts death risk by 62% in coronavirus patients, new study shows

Published on 13/07/20 at 10:28am
U.S. Army photo by Jason W. Edwards

Gilead’s remdesivir reduced the risk of death in 62% of severe COVID-19 patients, according to a new study.

The company released a statement which said: “The analysis demonstrated that remdesivir treatment was associated with the significantly improved clinical recovery and a 62 percent reduction in the risk of mortality compared to standard of care.” 

This latest Phase 3 SIMPLE trial included 312 patients being treated with Gilead’s drug compared with 818 being in the standard care group with both groups showing a similar severity of the virus.

74.4% of the remdesivir group recovered by day 14, versus 59% of the standard care group. It also showed that 7.6% of the group being treated with the drug died compared to 12.5% of the care group meaning it cut the death risk by 62%. Gilead also stated that its compassionate use program demonstrated that 83% of 77 pediatric patients and 92% of 86 pregnant and postpartum women recovered from the virus by day 28.

South Korea has started to provide the treatment free of charge through the Ministry of Food and Drug Safety’s special import program. However, from August patients will have to pay the medical costs.

Conor Kavanagh

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches